natgillin/translations-raw huggingface dataset:
In patients initially not reperfused, the incidence of severe haemorrhage was 1.2% for fondaparinux vs 1.5% for controls.
Pri bolnikih, pri katerih ni bila opravljena začetna reperfuzija je bila pojavnost hujše krvavitve 1,2 % za fondaparinuks v primerjavi z 1,5 % za kontrolo.
For patients receiving primary PCI, the incidence of severe haemorrhage was 1.0% for fondaparinux and 0.4% for controls.
Pri bolnikih, pri katerih je bila izvedena primarna PCI, je bila pojavnost hujše krvavitve 1,0 % pri fondaparinuksu in 0,4 % pri kontroli.
At Day 9 the incidence of major bleeding on fondaparinux and enoxaparin was 2.1% and 4.1%, respectively (hazard ratio 0.52, 95% CI, 0.44;0.61, p < 0.001).
Do 9. dne je bila pojavnost večje krvavitve pri fondaparinuksu 2,1 %, pri enoksaparinu pa 4,1 % (razmerje tveganja 0,52, 95 % interval zaupanja, 0,44;0,61, p < 0,001).
Type I glass barrel (1 ml) affixed with a 27 gauge x 12.7 mm needle and stoppered with a bromobutyl or chlorobutyl elastomer plunger stopper.
Injekcijska brizga (1 ml) iz stekla tipa I, s pritrjeno injekcijsko iglo G 27 x 12,7 mm in zaprta z batno zaporko iz bromobutilnega ali klorobutilnega elastomera.
The pharmacokinetics of fondaparinux has not been studied in patients with severe hepatic impairment (see sections 4.2 and 4.4).
Pri bolnikih s hudo okvaro jeter farmakokinetike fondaparinuksa niso raziskovali (glejte poglavji 4.2 in 4.4).
The mean (CV%) steady state pharmacokinetic parameters estimates of fondaparinux in patients with VTE receiving the fondaparinux proposed dose regimen once daily are: Cmax (mg/l) - 1.41 (23 %), Tmax (h) - 2.4 (8%) and Cmin (mg/l) -0.52 (45 %).
Srednje (CV%) ocene farmakokinetičnih parametrov za fondaparinuks v stanju dinamičnega ravnovesja pri bolnikih z VTE, ki so prejemali predlagano shemo odmerjanja fondaparinuksa enkrat na dan, so: Cmax (mg/l) - 1,41 (23 %), Tmax (h) - 2,4 (8 %) in Cmin (mg/l) -0,52 (45 %).
Read the package leaflet before use.
Subkutana uporaba Pred uporabo preberite priloženo navodilo.
If a patient is to undergo percutaneous coronary intervention (PCI), unfractionated heparin (UFH) as per standard practice should be administered during PCI, taking into account the patient's potential risk of bleeding, including the time since the last dose of fondaparinux (see section 4.4).
Če bo pri bolniku opravljena perkutana koronarna intervencija (PCI, “percutaneous coronary intervention”), mora bolnik med PCI prejeti nefrakcionirani heparin (UFH, “unfractionated heparin”) v skladu s standardno prakso, pri čemer je treba upoštevati možno tveganje za pojav krvavitev, vključno s časom, ko je bolnik prejel zadnji odmerek fondaparinuksa (glejte poglavje 4.4).
Treatment of Deep Venous Thrombosis
Zdravljenje globoke venske tromboze
Inject ALL of the contents of the syringe by pressing down on the plunger as far as it goes (picture E).
S potiskanjem bata navzdol do konca injicirajte VSO vsebino injekcijske brizge (slika E).
Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis (see sections 4.2 and 5.1).
Zdravljenje akutne simptomatske spontane povrhnje venske tromboze spodnjih udov brez sočasne globoke venske tromboze (glejte poglavji 4.2 in 5.1).
Syringe with an automatic needle protection system
Injekcijska brizga s samodejnim sistemom za zaščito igle
7.5 mg once a day
7,5 mg enkrat na dan večja od 100 kg
Adverse reactions in patients undergoing major orthopaedic surgery of lower limbs and/or abdominal surgery
Neželeni učinki pri bolnikih, ki so imeli večje ortopedske operacije spodnjih udov in/ali kirurški poseg v trebušni votlini
By binding selectively to antithrombin, fondaparinux potentiates (about 300 times) the innate neutralization of Factor Xa by antithrombin.
S selektivno vezavo na antitrombin fondaparinuks ojača (približno 300-krat) naravno nevtralizacijo faktorja Xa z antitrombinom.
The intravenous tubing should be well flushed with saline after injection to ensure that all of the medicinal product is administered.
Po injiciranju morate intravensko linijo dobro sprati s fiziološko raztopino, da boste zanesljivo aplicirali celotno količino zdravila.
Instruction on self-administration by subcutaneous injection is included in the Package Leaflet.
Napotki za subkutano samoinjiciranje so navedeni v navodilu za uporabo.
• if you notice any particles in the solution, or if the solution is discoloured
• če ste v raztopini opazili kakršnekoli delce ali spremembo barve;
In the subgroup of patients treated with fondaparinux or enoxaparin who underwent PCI, 8.8% and 8.2% of patients respectively, experience death/MI/RI within 9 days of randomisation (hazard ratio 1.08, 95% CI, 0.92;1.27).
Pri podskupini bolnikov, ki so se zdravili s fondaparinuksom ali enoksaparinom in pri katerih je bila izvedena PCI, so o smrtnem izidu/MI/RI v 9 dneh po randomizaciji poročali pri 8,8 % bolnikov, ki so prejemali fondaparinuks in 8,2 % bolnikov, ki so prejemali enoksaparin (razmerje tveganja 1,08, 95
• if you have very severe kidney disease.
• če imate zelo hudo bolezen ledvic.
In patients treated with primary PCI, the incidence of death/re-MI at Day 30 was not statistically different between the two groups [6.0% in fondaparinux group vs 4.8% in the control group; hazard ratio 1.26, 95% CI, 0.96, 1.66].
Pri bolnikih, pri katerih je bila opravljena primarna PCI niso opazili statistično pomembne razlike pri smrtnosti/pojavnosti re-MI do 30. dne med obema skupinama [6,0 % v skupini, ki je prejemala fondaparinuks v primerjavi s 4,8 % v kontrolni skupini; razmerje tveganja 1,26, 95 % interval zaupanja, 0,96, 1,66].
Rare: dyspnoea, coughing
Redki: dispneja, kašelj
Treatment of unstable angina/non- ST segment elevation myocardial infarction (UA/NSTEMI) The recommended dose of fondaparinux is 2.5 mg once daily, administered by subcutaneous injection.
Zdravljenje nestabilne angine pektoris/miokardnega infarkta brez dviga segmenta ST (UA/NSTEMI) Priporočeni odmerek fondaparinuksa je 2,5 mg enkrat na dan v obliki subkutane injekcije.
If a patient is to undergo non-primary PCI, unfractionated heparin (UFH) as per standard practice should be administered during PCI, taking into account the patient's potential risk of bleeding, including the time since the last dose of fondaparinux (see section 4.4).
Če bo pri bolniku opravljena neprimarna PCI, mora bolnik med PCI prejeti nefrakcionirani heparin (UHF) v skladu s standardno prakso, pri čemer je treba upoštevati možno tveganje za pojav krvavitev, vključno s časom, ko je bolnik prejel zadnji odmerek fondaparinuksa (glejte poglavje 4.4).
Hold the fold between the thumb and the forefinger during the entire injection (picture C).
Kožno gubo ves čas injiciranja držite s palcem in kazalcem (slika C).
The solution is a clear and colourless to slightly yellow liquid.
Raztopina je bistra in brezbarvna do rahlo rumenkasta tekočina.
Major bleeding during the initial treatment period was observed in 1.1% of fondaparinux patients, compared to 1.2% with enoxaparin.
Večjo krvavitev v začetnem obdobju zdravljenja so opazili pri 1,1 % bolnikov s fondaparinuksom in pri 1,2 % tistih z enoksaparinom.
Uncommon: headache Rare: dizziness
Občasni: glavobol Redki: omotica
Syringe with a manual needle protection system showing security sleeve being pulled over needle AFTER USE
Slika prikazuje varnostni tulec, nameščen preko igle PO UPORABI
Of the patients in the fondaparinux group, 5.8% experienced an event by Day 9 compared to 5.7% for enoxaparin-treated patients (hazard ratio 1.01, 95% CI, 0.90, 1.13, one-sided non-inferiority p value = 0.003).
V skupini s fondaparinuksom se je dogodek do 9. dne pojavil pri 5,8 bolnikov, v skupini, ki je prejemala enoksaparin pa pri 5,7 % bolnikov (razmerje tveganja 1,01, 95 % interval zaupanja, 0,90; 1,13, enostranska neinferiorna p vrednost = 0,003).
Mean (CV%) steady state pharmacokinetic parameters estimates of fondaparinux in patients undergoing hip replacement surgery receiving fondaparinux 2.5 mg once daily are: Cmax (mg/l) - 0.39 (31%), Tmax (h) - 2.8 (18%) and Cmin (mg/l) -0.14 (56%).
Ocena povprečnih vrednosti (CV %) farmakokinetičnih parametrov za fondaparinuks v stanju dinamičnega ravnovesja pri bolnikih po kirurški zamenjavi kolka, ki so prejemali enkrat na dan 2,5 mg fondaparinuksa so: Cmax (mg/l) - 0,39 (31 %), Tmax (h) - 2,8 (18 %) in Cmin (mg/l) - 0,14 (56 %).
Contact a doctor immediately if you get these symptoms.
→ Če se vam pojavijo ti simptomi, se nemudoma posvetujte z zdravnikom.
In the predefined stratum comparing fondaparinux to UFH (patients treated with primary PCI (58.5%), fibrin-specific lytics (13%), non-fibrin-specific lytics (2.6%) and no reperfusion (25.9%), the effects of fondaparinux and UFH on the incidence of death/re-MI at Day 30 were not statistically different: respectively, 8.3% vs 8.7% (hazard ratio 0.94, 95% CI, 0.79, 1.11 p = 0.460).
Pri v naprej določeni skupini, pri kateri so fondaparinuks primerjali z UFH (bolniki, zdravljeni s primarno PCI (58,5 %), fibrinsko specifičnimi litiki (13 %), fibrinsko nespecifičnimi litiki (2,6) in brez reperfuzije (25,9)), se učinka fondaparinuksa in UFH na zmanjšanje smrtnosti/pojavnosti re-MI do 30. dne nista statistično pomembno razlikovala, in sicer sta bila 8,3 % za fondaparinuks in 8,7 % za UFH (razmerje tveganja 0,94, 95 % interval zaupanja, 0,79;1,11 p = 0,460).
· bleeding disorders
· boleznijo strjevanja krvi,
The mortality rates were low and similar between the treatments groups with 2 (0.1%) deaths in the fondaparinux group versus 1 (0.1%) death in the placebo group.
Deleži umrljivosti so bili majhni in so bili med terapevtskima skupinama podobni: v skupini, ki je prejemala fondaparinuks, so zabeležili 2 smrti (0,1 %) in v skupini, ki je prejemala placebo, 1 smrt (0,1 %).
By binding selectively to ATIII, fondaparinux potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII.
S selektivno vezavo na ATIII fondaparinuks ojača (približno 300-krat) naravno nevtralizacijo Xa z ATIII.
In the predefined stratum comparing fondaparinux to placebo (i.e patients treated with nonfibrin specific lytics (77.3%), no reperfusion (22%), fibrin-specific lytics (0.3%), primary PCI (0.4%), the incidence of death/re-MI at Day 30 was significantly reduced from 14.0% on placebo to 11.3% (hazard ratio 0.80, 95% CI, 0.69, 0.93, p = 0.003).
Pri v naprej določenih skupinah pri katerih so fondaparinuks primerjali s placebom (to je bolniki, ki so se zdravili s fibrinsko nespecifičnimi litiki (77,3%), brez reperfuzije (22 %), fibrinsko specifičnimi litiki (0,3 %) primarno PCI (0,4 %)) se je smrtnost/pojavnost re-MI do 30. dne pomembno zmanjšala s 14,0 % pri placebu na 11,3 % (razmerje tveganja 0,80, 95 % interval zaupanja, 0,69;0,93, p = 0,003).
In hip fracture patients, associated with their increased age, fondaparinux steady state plasma concentrations are: Cmax (mg/l) - 0.50 (32%), Cmin (mg/l) - 0.19 (58%).
Pri bolnikih z zlomom kolka, povezanim z njihovo višjo starostjo, so plazemske koncentracije fondaparinuksa v stanju dinamičnega ravnovesja: Cmax (mg/l) - 0,50 (32 %), Cmin (mg/l) - 0,19 (58 %).
Type I glass barrel (1 ml) affixed with a 27 gauge x 12.7 mm needle and stoppered with a chlorobutyl elastomer plunger stopper.
Injekcijska brizga (1 ml) iz stekla tipa I, s pritrjeno injekcijsko iglo G 27 x 12,7 mm in zaprta z batno zaporko iz klorobutilnega elastomera.
Fondaparinux is known to be excreted mainly by the kidney.
Znano je, da se fondaparinuks izloča večinoma skozi ledvici.
These may affect more than 1 in 100 people treated with Arixtra.
Pojavijo se lahko pri več kot 1 od 100 bolnikov, ki se zdravijo z zdravilom Arixtra.
Hepatobiliary disorders Uncommon: abnormal liver function, hepatic enzymes increased
Občasni: nenormalno delovanje jeter, zvišanje jetrnih encimov
Major vascular access site complications
Večji zapleti na mestu žilnega dostopa
The incidence of adjudicated major bleeding was 2.1% (fondaparinux) vs. 4.1% (enoxaparin) up to and including Day 9 in the Phase III UA/NSTEMI study, and the incidence of adjudicated severe haemorrhage by modified TIMI criteria was 1.1% (fondaparinux) vs. 1.4% (control [UFH/placebo]) up to and including Day 9 in the Phase III STEMI study.
V študiji III. faze STEMI je bila do in vključno z 9. dnem pojavnost hujših krvavitev po modificiranih kriterijih TIMI 1,1 % (fondaparinuks) v primerjavi z 1,4 % (kontrola [UFH/placebo]).
Nervous system disorders Rare: anxiety, somnolence, vertigo, dizziness, headache, confusion
Redki: anksioznost, somnolenca, vrtoglavica, omotica, glavobol, zmedenost
The adverse reactions reported by the investigator as at least possibly related to fondaparinux are presented within each frequency grouping (very common ≥ 1/10; common: ≥1/100 to < 1/10; uncommon: ≥ 1/1,000 to < 1/100; rare: ≥ 1/10,000 to <1/1,000; very rare <1/10,000) and system organ class by decreasing order of seriousness.
Neželeni učinki, o katerih so poročali raziskovalci in za katere je možna vsaj majhna povezava s fondaparinuksom, so navedeni v skupinah glede na pogostnost (zelo pogosti ≥ 1/10; pogosti ≥ 1/100 do < 1/10; občasni ≥ 1/1.000 do < 1/100; redki ≥ 1/10.000 do < 1/1.000; zelo redki < 1/10.000) in organski sistem v padajočem vrstnem redu po resnosti.
Low body weight
Majhna telesna masa
There is no experience in the subgroup of patients with both high body weight (>100 kg) and moderate renal impairment (creatinine clearance 30-50 ml/min).
S podskupino bolnikov, ki imajo tako preveliko telesno maso (> 100 kg) kot tudi zmerno okvaro ledvic (očistek kreatinina 30-50 ml/min), nimamo nobenih izkušenj.
Renal impairment - Compared with patients with normal renal function (creatinine clearance > 80 ml/min) undergoing orthopaedic surgery and receiving fondaparinux 2.5 mg once daily, plasma clearance is 1.2 to 1.4 times lower in patients with mild renal impairment (creatinine clearance 50 to 80 ml/min) and on average 2 times lower in patients with moderate renal impairment (creatinine clearance 30 to 50 ml/min).
Okvara ledvic - V primerjavi z bolniki z normalnim delovanjem ledvic (kreatininski očistek > 80 ml/min), ki so imeli ortopedsko operacijo in so dobivali fondaparinuks v odmerku 2,5 mg enkrat na dan, je pri bolnikih z blago okvaro delovanja ledvic (kreatininski očistek 50 do 80 ml/min) plazemski očistek 1,2 do 1,4- krat manjši in v povprečju 2-krat manjši pri bolnikih z zmerno okvaro delovanja ledvic (kreatininski očistek 30 do 50 ml/min).
When required, concomitant therapy with vitamin K antagonist should be administered in accordance with the information of Section 4.5.
Kadar so nujni, moramo uvesti sočasno terapijo z antagonisti vitamina K, skladno s podatki v poglavju 4.5.
The pharmacokinetics of fondaparinux sodium are derived from fondaparinux plasma concentrations quantified via anti factor Xa activity.
Farmakokinetika natrijevega fondaparinuksata temelji na plazemskih koncentracijah fondaparinuksa, kvantitativno izmerjenih z aktivnostjo proti faktorju Xa.
Prevention of Venous Thromboembolic Events (VTE) in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery (see section 5.1).
Preprečevanje venskih trombemboličnih dogodkov (VTE) po kirurških posegih v trebušni votlini pri odraslih , pri katerih obstaja povečano tveganje za pojav trombemboličnih zapletov, npr. bolniki po resekciji tumorja v trebušni votlini (glejte poglavje 5.1).
• bleeding (for example from an operation site, an existing stomach ulcer, nosebleed, bruising)
• krvavitev (npr. iz rane na mestu operacije, razjede želodca, nosu, dlesni);
Low Dose UFH N = 1024
Nizek odmerek UFH
In patients undergoing surgery, timing of the first fondaparinux injection requires strict adherence in patients ≥75 years, and/or with body weight <50 kg and/or with renal impairment with creatinine clearance ranging between 20 to 50 ml/min.
Pri bolnikih z operacijami, starih ≥ 75 let in/ali težkih < 50 kg in/ali z ledvično okvaro s kreatininskim očistkom v razponu od 20 do 50 ml/min, se je treba strogo držati pravilnega časa prve injekcije fondaparinuksa.
What Arixtra looks like and contents of the pack Arixtra is a clear and colourless solution for injection.
Zdravilo Arixtra je bistra in brezbarvna raztopina za injiciranje.
In patients given a thrombolytic, severe haemorrhage occurred in 1.3% of the fondaparinux patients and in 2.0% of controls.
Pri bolnikih, ki so prejeli trombolitik, se je hujša krvavitev pojavila pri 1,3 % bolnikov, ki so prejemali fondaparinuks in 2,0 % bolnikov v kontrolni skupini.
At the doses used for treatment, fondaparinux does not, to a clinically relevant extent, affect routine coagulation tests such as activated partial thromboplastin time (aPTT), activated clotting time (ACT) or prothrombin time (PT)/International Normalised Ratio (INR) tests in plasma nor bleeding time or fibrinolytic activity.
V odmerkih, ki se uporabljajo pri zdravljenju, fondaparinuks ne vpliva, v klinično pomembnem obsegu, na rutinske koagulacijske teste v plazmi, kot so merjenje aktiviranega parcialnega tromboplastinskega časa (aPTT), aktiviranega časa nastanka strdka (ACT) ali razmerja protrombinski čas (PT)/internacionalno normalizirano razmerje (INR), niti na čas krvavitve ali fibrinolitično aktivnost, vendar pa so bila pridobljena redka spontana poročila o podaljšanju aPTT.
Slide the sleeve up the body of the syringe until it locks into position over the needle.
Tulec potisnite po telesu injekcijske brizge navzgor, dokler ne pokrije injekcijske igle in se zaskoči.
In a randomised, double-blind, clinical trial in patients with a confirmed diagnosis of acute symptomatic DVT, fondaparinux 5 mg (body weight < 50 kg), 7.5 mg (body weight ≥ 50 kg, ≤ 100 kg) or 10 mg (body weight >100 kg) SC once daily was compared to enoxaparin sodium 1 mg/kg SC twice daily.
V randomiziranem, dvojno slepem kliničnem preskušanju pri bolnikih s potrjeno diagnozo akutne simptomatske DVT so fondaparinuks v odmerkih 5 mg (telesna masa < 50 kg), 7,5 mg (telesna masa ≥ 50 kg, ≤ 100 kg) ali 10 mg (telesna masa > 100 kg) s.c. enkrat na dan primerjali z natrijevim enoksaparinatom v odmerku 1 mg/kg s.c. dvakrat na dan. Zdravili so vsega skupaj 2.192 bolnikov; bolnike iz obeh skupin so zdravili vsaj po 5 dni in do 26 dni dolgo (povprečno po 7 dni).
Paediatric population - Fondaparinux is not recommended for use in children below 17 years of age due to a lack of data on safety and efficacy.
Otroci - Zaradi pomanjkanja podatkov o varnosti in učinkovitosti uporaba fondaparinuksa pri otrocih, mlajših od 17 let, ni priporočljiva.
• if you notice that the syringe is damaged
• če je injekcijska brizga poškodovana;
No dosage reduction is required for patients with creatinine clearance > 20 ml/min.
Pri bolnikih s kreatininskim očistkom 20 ml/min odmerka ni treba prilagajati.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, and genotoxicity.
Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih in genotoksičnosti ne kažejo posebnega tveganja za človeka.
INFORMATION IN BRAILLE arixtra 7.5 mg
arixtra 7.5 mg
In patients >75 years undergoing orthopaedic surgery and receiving fondaparinux 2.5 mg once daily, the estimated plasma clearance was 1.2 to 1.4 times lower than in patients <65 years.
Pri bolnikih, > 75 let, ki so imeli ortopedsko operacijo in so dobivali fondaparinuks v odmerku 2,5 mg enkrat na dan, je ocenjeni očistek plazme 1,2 do 1,4krat manjši kot pri bolnikih, < 65 let.
Common: bleeding (gastrointestinal, haematuria, haematoma, epistaxis, haemoptysis, utero-vaginal haemorrhage, haemarthrosis, ocular, purpura, bruise)
Pogosti: krvavitve (gastrointestinalne, hematurija, hematom, epistaksa, hemoptiza, krvavitve iz maternice in nožnice, hemartroza, očesne krvavitve, purpura, modrice)
In patients who were revascularised with a thrombolytic, fondaparinux significantly reduced the incidence of death/re-MI at Day 30 from 13.6% for the control group to 10.9% (hazard ratio 0.79, 95%CI, 0.68;0.93, p = 0.003).
Pri bolnikih, pri katerih je bila opravljena revaskularizacija s trombolitikom, je fondaparinuks do 30. dne pomembno zmanjšal smrtnost/pojavnost re-MI iz 13,6 % v kontrolni skupini na 10,9 % (razmerje tveganja 0,79, 95 % interval zaupanja, 0,68;0,93, p = 0,003).
Paediatric patients - Fondaparinux has not been investigated in this population for the prevention of VTE or for the treatment of superficial vein thrombosis.
Pediatrični bolniki - Uporabe fondaparinuksa za preprečevanje VTE ali za zdravljenje povrhnje venske tromboze pri otrocih niso proučevali.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER BOX
PODATKI NA ZUNANJI OVOJNINI ŠKATLA
Renal impairment - Compared with patients with normal renal function (creatinine clearance > 80 ml/min), plasma clearance is 1.2 to 1.4 times lower in patients with mild renal impairment (creatinine clearance 50 to 80 ml/min) and on average 2 times lower in patients with moderate renal impairment (creatinine clearance 30 to 50 ml/min).
Okvara ledvic - V primerjavi z bolniki z normalnim delovanjem ledvic (kreatininski očistek > 80 ml/min) je pri bolnikih z blago okvaro delovanja ledvic (kreatininski očistek 50 do 80 ml/min) plazemski očistek 1,2 do 1,4- krat manjši in v povprečju 2-krat manjši pri bolnikih z zmerno okvaro delovanja ledvic (kreatininski očistek 30 do 50 ml/min).
For step-by-step instructions please see over the page.
Postopna navodila za uporabo se nahajajo na drugi strani tega navodila.
The Arixtra pre-filled syringes have been designed with a needle protection system to prevent needle stick injuries following injection.
Arixtra napolnjene injekcijske brizge so opremljene s sistemom za zaščito igle, ki omogoča zaščito pred vbodom z iglo po injiciranju.
In patients >75 years undergoing orthopaedic surgery, the estimated plasma clearance was 1.2 to 1.4 times lower than in patients <65 years.
Pri bolnikih, > 75 let z ortopedskimi operacijami, je ocenjeni očistek plazme 1,2 do 1,4-krat manjši kot pri bolnikih, < 65 let.
STEP BY STEP GUIDE TO USING ARIXTRA
NAVODILA ZA UPORABO ZDRAVILA ARIXTRA Navodila za uporabo
• Prevention of VTE - No dosing adjustment is necessary in patients with either mild or moderate hepatic impairment.
• Preprečevanje VTE - Pri bolnikih z blago ali zmerno okvaro jeter odmerka ni treba prilagajati.
There are no data regarding the use of fondaparinux 2.5 mg in superficial-vein thrombosis patients with concomitant DVT or with superficial-vein thrombosis within 3 cm of the sapheno-femoral junction (see section 4.2 and 5.1).
O uporabi 2,5 mg fondaparinuksa pri bolnikih s povrhnjo vensko trombozo, ki imajo sočasno globoko vensko trombozo ali imajo povrhnjo vensko trombozo manj kot 3 cm od safeno-femoralnega spoja, ni podatkov (glejte poglavji 4.2 in 5.1).
Uncommon: dyspnoea
Občasni: dispneja
• if you have kidney disease
• če imate ledvično bolezen;
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology and genotoxicity.
Predklinični podatki na osnovi običajnih študij farmakološke varnosti in genotoksičnosti ne kažejo posebnega tveganja za človeka.
At the 2.5 mg dose, fondaparinux does not affect routine coagulation tests such as activated partial thromboplastin time (aPTT), activated clotting time (ACT) or prothrombin time (PT)/International Normalised Ratio (INR) tests in plasma nor bleeding time or fibrinolytic activity.
V odmerku 2,5 mg, fondaparinuks ne vpliva na rutinske koagulacijske teste v plazmi, kot so merjenje aktiviranega parcialnega tromboplastinskega časa (aPTT), aktiviranega časa nastanka strdka (ACT) ali razmerja protrombinski čas (PT)/internacionalno normalizirano razmerje (INR), niti na čas krvavitve ali fibrinolitično aktivnost, vendar pa so bila pridobljena redka spontana poročila o podaljšanju aPTT.